Targeting the endocannabinoid system with cannabinoid receptor agonists: Pharmacological strategies and therapeutic possibilities

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 367, Issue 1607, 2012, Pages 3353-3363

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

And CB2; Blood brain barrier; Cannabinoid CB1; Cannabinoid receptor agonists; Receptors; Therapeutic applications and strategies; 9 tetrahydrocannabinol

Indexed keywords

EID: 84868128338     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2011.0381     Document Type: Review

References (129)

1. Pertwee, R. G. 2005 The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 7, E625-E654. doi:10.1208/aapsj070364)
2. Le Foll, B., Gorelick, D. A. & Goldberg, S. R. 2009 The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology 205, 171-174. doi:10.1007/s00213-009-1506-7)
3. Pertwee, R. G. 2009 Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156, 397-411. doi:10.1111/j.1476-5381.2008.00048.x)
4. Pertwee, R. G. & Thomas, A. 2009 Therapeutic applications for agents that act at CB1 and CB2 receptors. In The cannabinoid receptors (ed. P. H. Reggio), pp. 361-392, 1st edn. New York, NY: Humana Press.
5. Pertwee, R. G. 2007 Cannabinoids and multiple sclerosis. Mol. Neurobiol. 36, 45-59. doi:10.1007/s12035-007-0005-2)
6. Petrosino, S. & Di Marzo, V. 2010 FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs 11, 51-62.
7. Dziadulewicz, E. K. et al. 2007 Naphthalen-1-yl- (4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J. Med. Chem. 50, 3851-3856. doi:10.1021/jm070317a)
8. Boyce, S. 2008 Targeting peripheral cannabinoid 1 (CB1) receptors for chronic pain. Fundam. Clin. Pharmacol. 22(Suppl. 2), 5-28. doi:10.1111/j.1472-8206.2008.00591.x)
9. Groblewski, T. et al. 2010 Pre-clinical pharmacological properties of novel peripherally-acting CB1-CB2 agonists. In 20th Annu. Symp. on the Cannabinoids; 2010, p. 37. Research Triangle Park, NC: Int. Cannabinoid Research Society.
10. Yu, X. H., Cao, C. Q., Martino, G., Puma, C., Morinville, A., St-Onge, S., Lessard, É., Perkins, M. N. & Laird, J. M. A. 2010 A peripherally restricted cannabinoid receptor agonist produces robust antinociceptive effects in rodent models of inflammatory and neuropathic pain. Pain 151, 337-344. doi:10.1016/j.pain.2010.07.019)
11. Rahn, E. J., Thakur, G. A., Wood, J. A. T., Zvonok, A. M., Makriyannis, A. & Hohmann, A. G. 2011 Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol. Biochem. Behav. 98, 493-502. doi:10.1016/j.pbb.2011.02.024)
12. van der Stelt, M. et al. 2011 Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists. J. Med. Chem. 54, 7350-7362. doi:10.1021/jm200916p)
13. Gijsen, H. J. M., De Cleyn, M. A. J., Surkyn, M., Van Lommen, G. R. E., Verbist, B. M. P., Nijsen, M. J. M. A., Meert, T., Van Wauwe, J. & Aerssens, J. 2012 5-Sulfonyl-benzimidazoles as selective CB2 agonists: part 2. Bioorg. Med. Chem. Lett. 22, 547-552. doi:10.1016/j.bmcl.2011.10.091)
14. Cheng, Y.-X. et al. 2012 G-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration. Bioorg. Med. Chem. Lett. 22, 1619-1624. doi:10.1016/j.bmcl.2011.12.124)
15. Adam, J. M. et al. 2012 Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain. Bioorg. Med. Chem. Lett. 22, 2932-2937. doi:10.1016/j.bmcl.2012.02.048)
16. Groblewski, T. et al. 2010 Peripherally-acting CB1-CB2 agonists for pain: do they still hold promise? In 20th Annu. Symp. on the Cannabinoids; 2010, p. 38. Research Triangle Park, NC: Int. Cannabinoid Research Society.
17. Cui, J. H., Kim, W. M., Lee, H. G., Kim, Y. O., Kim, C. M. & Yoon, M. H. 2011 Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model. Neurosci. Lett. 493, 67-71. doi:10.1016/j.neulet.2010.12.052)
18. Hama, A. & Sagen, J. 2011 Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception. Pharmacol. Biochem. Behav. 100, 340-346. doi:10.1016/j.pbb.2011.09.004)
19. Potenzieri, C., Harding-Rose, C. & Simone, D. A. 2008 The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain. Res. 1215, 69-75. doi:10.1016/j.brainres.2008.03.063)
20. Gu, X. P., Mei, F. M., Liu, Y., Zhang, R., Zhang, J. & Ma, Z. L. 2011 Intrathecal administration of the cannabinoid 2 receptor agonist JWH015 can attenuate cancer pain and decrease mRNA expression of the 2B subunit of N-methyl-D-aspartic acid. Anesth. Analg. 113, 405-411. doi:10.1213/ANE.0b013e31821d1062)
21. Khasabova, I. A., Chandiramani, A., Harding-Rose, C., Simone, D. A. & Seybold, V. S. 2011 Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol. Res. 64, 60-67. doi:10.1016/j.phrs.2011.03.007)
22. Khasabova, I. A., Gielissen, J., Chandiramani, A., Harding-Rose, C., Abu Odeh, D., Simone, D. A. & Seybold, V. S. 2011 CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav. Pharmacol. 22, 607-616. doi:10.1097/FBP.0b013e3283474a6d)
23. Dogrul, A., Gul, H., Akar, A., Yildiz, O., Bilgin, F. & Guzeldemir, E. 2003 Topical cannabinoid antinociception: synergy with spinal sites. Pain 105, 11-16. doi:10.1016/S0304-3959(03)00068-X)
24. Yesilyurt, O., Dogrul, A., Gul, H., Seyrek, M., Kusmez, O., Ozkan, Y. & Yildiz, O. 2003 Topical cannabinoid enhances topical morphine antinociception. Pain 105, 303-308. doi:10.1016/S0304-3959(03)00245-8)
25. Rukwied, R., Watkinson, A., McGlone, F. & Dvorak, M. 2003 Cannabinoid agonists attenuate capsaicininduced responses in human skin. Pain 102, 283-288. doi:10.1016/S0304-3959(02)00401-3)
26. Dvorak, M., Watkinson, A., McGlone, F. & Rukwied, R. 2003 Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm. Res. 52, 238-245. doi:10.1007/s00011-003-1162-z)
27. Magina, S., Esteves-Pinto, C., Moura, E., Serrão, M. P., Moura, D., Petrosino, S., Di Marzo, V. & Vieira-Coelho, M. A. 2011 Inhibition of basal and ultraviolet B-induced melanogenesis by cannabinoid CB1 receptors: a keratinocyte-dependent effect. Arch. Dermatol. Res. 303, 201-210. doi:10.1007/s00403-011-1126-z)
28. Whiteside, G. T., Lee, G. P. & Valenzano, K. J. 2007 The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr. Med. Chem. 14, 917-936. doi:10.2174/092986707780363023)
29. Guindon, J. & Hohmann, A. G. 2008 Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br. J. Pharmacol. 153, 319-334. doi:10.1038/sj.bjp.0707531)
30. Beltramo, M., Bernardini, N., Bertorelli, R., Campanella, M., Nicolussi, E., Fredduzzi, S. & Reggiani, A. 2006 CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. 23, 1530-1538. doi:10.1111/j.1460-9568.2006.04684.x)
31. Gutierrez, T., Crystal, J. D., Zvonok, A. M., Makriyannis, A. & Hohmann, A. G. 2011 Selfmedication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain 152, 1976-1987. doi:10.1016/j.pain.2011.03.038)
32. Paszcuk, A. F., Dutra, R. C., da Silva, K. A. B. S., Quintão, N. L. M., Campos, M. M. & Calixto, J. B. 2011 Cannabinoid agonists inhibit neuropathic pain induced by brachial plexus avulsion in mice by affecting glial cells and MAP kinases. PLoS ONE 6, e24034. doi:10.1371/journal.pone.0024034)
33. Bab, I., Smoum, R., Bradshaw, H. & Mechoulam, R. 2011 Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family. Br. J. Pharmacol. 163, 1441-1446. doi:10.1111/j.1476-5381.2011.01474.x)
34. Guindon, J. & Hohmann, A. G. 2011 The endocannabinoid system and cancer: therapeutic implication. Br. J. Pharmacol. 163, 1447-1463. doi:10.1111/j.1476-5381.2011.01327.x)
35. Odan, M. et al. 2012 Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent. Bioorg. Med. Chem. Lett. 22, 2803-2806. doi:10.1016/j.bmcl.2012.02.072)
36. Little, J. P., Villanueva, E. B. & Klegeris, A. 2011 Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease. Mini-Rev. Med. Chem. 11, 582-590.
37. Fernández-Ruiz, J. et al. 2011 Prospects for cannabinoid therapies in basal ganglia disorders. Br. J. Pharmacol. 163, 1365-1378. doi:10.1111/j.1476-5381.2011.01365.x)
38. Kim, K., Moore, D. H., Makriyannis, A. & Abood, M. E. 2006 AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol. 542, 100-105. doi:10.1016/j.ejphar.2006.05.025)
39. Shoemaker, J. L., Seely, K. A., Reed, R. L., Crow, J. P. & Prather, P. L. 2007 The CB2 cannabinoid agonist AM- 1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. 101, 87-98. doi:10.1111/j.1471-4159.2006.04346.x)
40. Dittel, B. N. 2008 Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. Br. J. Pharmacol. 153, 271-276. doi:10.1038/sj.bjp.0707493)
41. Basu, S. & Dittel, B. N. 2011 Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol. Res. 51, 26-38. doi:10.1007/s12026-011-8210-5)
42. Persidsky, Y., Ho, W. Z., Ramirez, S. H., Potula, R., Abood, M. E., Unterwald, E. & Tuma, R. 2011 HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. Brain Behav. Immun. 25, S61-S70. doi:10.1016/j.bbi.2011.03.001)
43. Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R. & Ozaita, A. 2011 Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol. Psychiatry 70, 479-486. doi:10.1016/j.biopsych.2011.04.022)
44. Navarrete, F., Pérez-Ortiz, J. M. & Manzanares, J. 2012 Cannabinoid CB2 receptor-mediated regulation of impulsive-like behaviour in DBA/2 mice. Br. J. Pharmacol. 165, 260-273. doi:10.1111/j.1476-5381.2011.01542.x)
45. Xi, Z.-X. et al. 2011 Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nat. Neurosci. 14, 1160-1166. doi:10.1038/nn.2874)
46. Elliott, M. B., Tuma, R. F., Amenta, P. S., Barbe, M. F. & Jallo, J. I. 2011 Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury. J. Neurotrauma 28, 973-981. doi:10.1089/neu.2010.1672)
47. Zhang, M., Martin, B. R., Adler, M.W., Razdan, R. K., Jallo, J. I. & Tuma, R. F. 2007 Cannabinoid CB2 receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J. Cereb. Blood Flow Metab. 27, 1387-1396. doi:10.1038/sj.jcbfm.9600447)
48. Pacher, P. & Haskó, G. 2008 Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br. J. Pharmacol. 153, 252-262. doi:10.1038/sj.bjp.0707582)
49. Steffens, S., Veillard, N. R., Arnaud, C., Pelli, G., Burger, F., Staub, C., Zimmer, A., Frossard, J.-L. & Mach, F. 2005 Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782-786. doi:10.1038/nature03389)
50. Hoyer, F. F., Steinmetz, M., Zimmer, S., Becker, A., Lütjohann, D., Buchalla, R., Zimmer, A. & Nickenig, G. 2011 Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J. Mol. Cell. Cardiol. 51, 1007-1014. doi:10.1016/j.yjmcc.2011.08.008)
51. Wright, K. L., Duncan, M. & Sharkey, K. A. 2008 Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br. J. Pharmacol. 153, 263-270. doi:10.1038/sj.bjp.0707486)
52. Izzo, A. A. & Camilleri, M. 2008 Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57, 1140-1155. doi:10.1136/gut.2008.148791)
53. Singh, U. P., Singh, N. P., Singh, B., Price, R. L., Nagarkatti, M. & Nagarkatti, P. S. 2012 Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-102/2 mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol. Appl. Pharmacol. 258, 256-267. doi:10.1016/j.taap.2011.11.005)
54. Mallat, A., Teixeira-Clerc, F., Deveaux, V. & Lotersztajn, S. 2007 Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin. Ther. Targets 11, 403-409. doi:10.1517/14728222.11.3.403)
55. Lotersztajn, S. et al. 2008 CB2 receptors as new therapeutic targets for liver diseases. Br. J. Pharmacol. 153, 286-289. doi:10.1038/sj.bjp.0707511)
56. Mallat, A., Teixeira-Clerc, F., Deveaux, V., Manin, S. & Lotersztajn, S. 2011 The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br. J. Pharmacol. 163, 1432-1440. doi:10.1111/j.1476-5381.2011.01397.x)
57. Huang, L., Quinn, M. A., Frampton, G. A., Golden, L. E. & DeMorrow, S. 2011 Recent advances in the understanding of the role of the endocannabinoid system in liver diseases. Dig. Liver Dis. 43, 188-193. doi:10.1016/j.dld.2010.08.010)
58. Louvet, A., Teixeira-Clerc, F., Chobert, M. N., Deveaux, V., Pavoine, C., Zimmer, A., Pecker, F., Mallat, A. & Lotersztajn, S. 2011 Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 54, 1217-1226. doi:10.1002/hep.24524)
59. Barutta, F. et al. 2011 Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 60, 2386-2396. doi:10.2337/db10-1809)
60. Bab, I., Zimmer, A. & Melamed, E. 2009 Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann. Med. 41, 560-567. doi:10.1080/07853890903121025)
61. Maher, S. A., Dubuis, E. D. & Belvisi, M. G. 2011 G-protein coupled receptors regulating cough. Curr. Opin. Pharmacol. 11, 248-253. doi:10.1016/j.coph.2011.06.005)
62. Guzmán, M. 2003 Cannabinoids: potential anticancer agents. Nat. Rev. Cancer 3, 745-755. doi:10.1038/nrc1188)
63. Malfitano, A. M., Ciaglia, E., Gangemi, G., Gazzerro, P., Laezza, C. & Bifulco, M. 2011 Update on the endocannabinoid system as an anticancer target. Expert Opin. Ther. Targets 15, 297-308. doi:10.1517/14728222.2011.553606)
64. Vara, D., Salazar, M., Olea-Herrero, N., Guzmán, M., Velasco, G. & Díaz-Laviada, I. 2011 Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 18, 1099-1111. doi:10.1038/cdd.2011.32)
65. Nasser, M. W., Qamri, Z., Deol, Y. S., Smith, D., Shilo, K., Zou, X. & Ganju, R. K. 2011 Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS ONE 6, e23901. doi:10.1371/journal.pone.0023901)
66. Gamaleddin, I., Zvonok, A., Makriyannis, A., Goldberg, S. R. & Le Foll, B. 2012 Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS ONE 7, e29900. doi:10.1371/journal.pone.0029900)
67. Ramirez, S. H. et al. 2012 Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J. Neurosci. 32, 4004-4016. doi:10.1523/JNEUROSCI.4628-11.2012)
68. Adhikary, S., Li, H., Heller, J., Skarica, M., Zhang, M., Ganea, D. & Tuma, R. F. 2011 Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury. J. Neurotrauma 28, 2417-2427. doi:10.1089/neu.2011.1853)
69. Pryce, G. & Baker, D. 2007 Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br. J. Pharmacol. 150, 519-525. doi:10.1038/sj.bjp.0707003)
70. Kinsey, S. G., Naidu, P. S., Cravatt, B. F., Dudley, D. T. & Lichtman, A.H. 2011 Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol. Biochem. Behav. 99, 718-725. doi:10.1016/j.pbb.2011.06.022)
71. Anavi-Goffer, S., Baillie, G., Irving, A. J., Gertsch, J., Greig, I. R., Pertwee, R. G. & Ross, R. A. 2012 Modulation of L-a-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J. Biol. Chem. 287, 91-104. doi:10.1074/jbc.M111.296020)
72. Finn, D. P., Beckett, S. R. G., Roe, C. H., Madjd, A., Fone, K. C. F., Kendall, D. A., Marsden, C. A. & Chapman, V. 2004 Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur. J. Neurosci. 19, 678-686. doi:10.1111/j.0953-816X.2004.03177.x)
73. Yoon, M. H. & Choi, J. 2003 Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. Anesthesiology 99, 701-707. doi:10.1097/00000542-200309000-00027)
74. Kang, S., Kim, C. H., Lee, H., Kim, D. Y., Han, J. I., Chung, R. K. & Lee, G. Y. 2007 Antinociceptive synergy between the cannabinoid receptor agonist WIN 55,212-2 and bupivacaine in the rat formalin test. Anesth. Analg. 104, 719-725. doi:10.1213/01.ane.0000255291.38637.26)
75. Guindon, J., De Léan, A. & Beaulieu, P. 2006 Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 121, 85-93. doi:10.1016/j.pain.2005.12.007)
76. Ruggieri, V., Vitale, G., Filaferro, M., Frigeri, C., Pini, L. A. & Sandrini, M. 2010 The antinociceptive effect of acetylsalicylic acid is differently affected by a CB1 agonist or antagonist and involves the serotonergic system in rats. Life Sci. 86, 510-517. doi:10.1016/j.lfs.2010.02.006)
77. Ahn, D. K., Choi, H. S., Yeo, S. P., Woo, Y. W., Lee, M. K., Yang, G. Y., Jeon, H. J., Park, J. S. & Mokha, S. S. 2007 Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception. Pain 132, 23-32. doi:10.1016/j.pain.2007.01.015)
78. Ulugöl, A., Özyigit, F., Yeşilyurt, Ö. & Dogrul, A. 2006 The additive antinociceptive interaction between WIN 55,212-2, a cannabinoid agonist, and ketorolac. Anesth. Analg. 102, 443-447. doi:10.1213/01.ane.0000194587.94260.1d)
79. 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of m- and k-opioid receptors. Eur. J. Pharmacol. 318, 11-16. doi:10.1016/S0014-2999(96)00752-2)
80. Pertwee, R. G. 2001 Cannabinoid receptors and pain. Prog. Neurobiol. 63, 569-611. doi:10.1016/S0301-0082(00)00031-9)
81. 9-tetrahydrocannabinol and opioids after oral administration. J. Pharmacol. Exp. Ther. 304, 1010-1015. doi:10.1124/jpet.102.045575)
82. Cichewicz, D. L. 2004 Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 74, 1317-1324. doi:10.1016/j.lfs.2003.09.038)
83. Tham, S. M., Angus, J. A., Tudor, E. M. & Wright, C. E. 2005 Synergistic and additive interactions of the cannabinoid agonist CP55,940 with μ opioid receptor and α2-adrenoceptor agonists in acute pain models in mice. Br. J. Pharmacol. 144, 875-884. doi:10.1038/sj.bjp.0706045)
84. 9-tetrahydrocannabinol. Eur. J. Pharmacol. 525, 74-82. doi:10.1016/j.ejphar.2005.09.039)
85. 9-tetrahydrocannabinol. Eur. J. Pharmacol. 539, 57-63. doi:10.1016/j.ejphar.2006.04.003)
86. 9-tetrahydrocannabinol and morphine in the arthritic rat. Eur. J. Pharmacol. 567, 125-130. doi:10.1016/j.ejphar.2007.04.010)
87. 9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur. J. Pharmacol. 571, 129-137. doi:10.1016/j.ejphar.2007.06.001)
88. 9-tetrahydrocannabinol and m opioid receptor agonists in rhesus monkeys: discrimination and antinociception. Psychopharmacology 199, 199-208. doi:10.1007/s00213-008-1157-0)
89. Welch, S. P. 2009 Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int. Rev. Psych. 21, 143-151. doi:10.1080/09540260902782794)
90. Fischer, B. D., Ward, S. J., Henry, F. E. & Dykstra, L. A. 2010 Attenuation of morphine antinociceptive tolerance by a CB1 receptor agonist and an NMDA receptor antagonist: interactive effects. Neuropharmacology 58, 544-550. doi:10.1016/j.neuropharm.2009.08.005)
91. Fang, Q., Han, Z.-L., Li, N., Wang, Z.-L., He, N. & Wang, R. 2012 Effects of neuropeptide FF system on CB1 and CB2 receptors mediated antinociception in mice. Neuropharmacology 62, 855-864. doi:10.1016/j.neuropharm.2011.09.013)
92. Holdcroft, A., Smith, M., Jacklin, A., Hodgson, H., Smith, B., Newton, M. & Evans, F. 1997 Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 52, 483-488. doi:10.1111/j.1365-2044.1997.139-az0132.x)
93. Narang, S., Gibson, D., Wasan, A. D., Ross, E. L., Michna, E., Nedelikovic, S. S. & Jamison, R. N. 2008 Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J. Pain 9, 254-264. doi:10.1016/j.jpain.2007.10.018)
94. Abrams, D. I., Couey, P., Shade, S. B., Kelly, M. E. & Benowitz, N. L. 2011 Cannabinoid-opioid interaction in chronic pain. Clin. Pharmacol. Ther. 90, 844-851. doi:10.1038/clpt.2011.188)
95. 9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain. Anaesthesist 55, 391-400. doi:10.1007/s00101-005-0963-6)
96. Naef, M., Curatolo, M., Petersen-Felix, S., Arendt-Nielsen, L., Zbinden, A. & Brenneisen, R. 2003 The analgesic effect of oral D-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105, 79-88. doi:10.1016/S0304-3959(03)00163-5)
97. Roberts, J. D., Gennings, C. & Shih, M. 2006 Synergistic affective analgesic interaction between Δ-9-tetrahydrocannabinol and morphine. Eur. J. Pharmacol. 530, 54-58. doi:10.1016/j.ejphar.2005.11.036
98. Naderi, N., Haghparast, A., Saber-Tehrani, A., Rezaii, N., Alizadeh, A.-M., Khani, A. & Motamedi, F. 2008 Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol. Biochem. Behav. 89, 64-75. doi:10.1016/j.pbb.2007.11.001)
99. 9-tetrahydrocannabinol and nicotine. Br. J. Pharmacol. 135, 564-578. doi:10.1038/sj.bjp.0704479)
100. Balerio, G. N., Aso, E. & Maldonado, R. 2006 Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology 184, 504-513. doi:10.1007/s00213-005-0251-9)
101. 9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur. J. Pharmacol. 555, 156-163. doi:10.1016/j.ejphar.2006.10.038)
102. Adamczyk, P., Golda, A., McCreary, A. C., Filip, M. & Przegalński, E. 2008 Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J. Physiol. Pharmacol. 59, 217-228.
103. Bahremand, A., Shafaroodi, H., Ghasemi, M., Nasrabady, S. E., Gholizadeh, S. & Dehpour, A. R. 2008 The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice. Epilepsy Res. 81, 44-51. doi:10.1016/j.eplepsyres.2008.04.010)
104. Luszczki, J. J., Andres-Mach, M., Barcicka-Klosowska, B., Florek-Luszczki, M., Haratym-Maj, A. & Czuczwar, S. J. 2011 Effects of WIN 55,212-2 mesylate (a synthetic cannabinoid) on the protective action of clonazepam, ethosuximide, phenobarbital and valproate against pentylenetetrazole-induced clonic seizures in mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35, 1870-1876. doi:10.1016/j.pnpbp.2011.07.001)
105. Luszczki, J. J., Misiuta-Krzesinska, M., Florek, M., Tutka, P. & Czuczwar, S. J. 2011 Synthetic cannabinoid WIN 55,212-2 mesylate enhances the protective action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol. Biochem. Behav. 98, 261-267. doi:10.1016/j.pbb.2011.01.002)
106. Luszczki, J. J., Czuczwar, P., Cioczek-Czuczwar, A., Dudra-Jastrzebska, M., Andres-Mach, M. & Czuczwar, S. J. 2010 Effect of arachidonyl-2 '-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the protective action of the various antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 34, 18-25. doi:10.1016/j.pnpbp.2009.09.005)
107. Naderi, N., Ahari, F. A., Shafaghi, B., Najarkolaei, A.H. & Motamedi, F. 2008 Evaluation of nteractions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J. Neural. Transm. 115, 1501-1511. doi:10.1007/s00702-008-0076-x)
108. Bhattacharjee, H., Nadipuram, A., Kosanke, S., Kiani, M. F. & Moore, B. M. 2011 Low-volume binary drug therapy for the treatment of hypovolemia. Shock 35, 590-596. doi:10.1097/SHK.0b013e3182150e80)
109. Szczesniak, A.-M., Maor, Y., Robertson, H., Hung, O. & Kelly, M. E. M. 2011 Nonpsychotropic cannabinoids, abnormal cannabidiol and cannabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure. J. Ocular Pharmacol. Ther. 27, 427-435. doi:10.1089/jop.2011.0041)
110. Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández-Tiedra, S., Salazar, M., García-Taboada, E., Barcia, J., Guzmán, M. & Velasco, G. 2011 A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol. Cancer Ther. 10, 90-103. doi:10.1158/1535-7163.mct-10-0688)
111. Kwiatkowska, M., Parker, L. A., Burton, P. & Mechoulam, R. 2004 A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174, 254-259. doi:10.1007/s00213-003-1739-9)
112. Donadelli, M. et al. 2011 Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2, e152. doi:10.1038/cddis.2011.36)
113. Paquette, J. J., Wang, H.-Y., Bakshi, K. & Olmstead, M.C. 2007 Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant. Behav. Pharmacol. 18, 767-776. doi:10.1097/FBP.0b013e 3282f15890)
114. Gholizadeh, S., Shafaroodi, H., Ghasemi, M., Bahremand, A., Sharifzadeh, M. & Dehpour, A. R. 2007 Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice. Neuropharmacology 53, 763-770. doi:10.1016/j.neuropharm.2007.08.005)
115. 8-Tetrahydrocannabivarin protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress and inflammatory response via CB2 receptors. Br. J. Pharmacol. 165, 2450-2461. doi:10.1111/j.1476-5381.2011.01410.x)
116. 9-THCV in animal models of Parkinson's disease. Br. J. Pharmacol. 163, 1495-1506. doi:10.1111/j.1476-5381.2011.01278.x)
117. Marquart, S. et al. 2010 Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum. 62, 3467-3476. doi:10.1002/art.27642)
118. Zhang, M., Martin, B. R., Adler, M.W., Razdan, R. K., Ganea, D. & Tuma, R. F. 2008 Modulation of the balance between cannabinoid CB1 and CB2 receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 152, 753-760. doi:10.1016/j.neuroscience.2008.01.022)
119. Le Foll, B. & Goldberg, S. R. 2005 Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J. Pharmacol. Exp. Ther. 312, 875-883. doi:10.1124/jpet.104.077974)
120. 9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br. J. Pharmacol. 160, 677-687. doi:10.1111/j.1476-5381.2010.00756.x)
121. 9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199-215. doi:10.1038/sj.bjp.0707442)
122. Manzanedo, C., Aguilar, M. A., Rodríguez-Arias, M., Navarro, M. & Miñarro, J. 2004 Cannabinoid agonistinduced sensitisation to morphine place preference in mice. Neuroreport 15, 1373-1377. doi:10.1097/01.wnr.000012621787116.8c)
123. Ellgren, M., Spano, S. M. & Hurd, Y. L. 2007 Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32, 607-615. doi:10.1038/sj.npp.1301127)
124. Pertwee, R. G. 1992 In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. In Marijuana/cannabinoids: neurobiology and neurophysiology (eds L. Murphy & A. Bartke), pp. 165-218, 1st edn. Boca Raton, FL: CRC Press.
125. 9-THC-treated rats: possible clinical implications. Br. J. Pharmacol. 140, 520-526. doi:10.1038/sj.bjp.0705478)
126. Tumati, S., Largent-Milnes, T. M., Keresztes, A., Ren, J. Y., Roeske, W. R., Vanderah, T. W. & Varga, E. V. 2012 Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. J. Neuroimmunol. 244, 23-31. doi:10.1016/j.jneuroim.2011.12.021)
127. Romero-Sandoval, A. & Eisenach, J. C. 2007 Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 106, 787-794. doi:10.1097/01.anes.0000264765.33673.6c)
128. Yamamoto, W., Mikami, T. & Iwamura, H. 2008 Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur. J. Pharmacol. 583, 56-61. doi:10.1016/j.ejphar.2008.01.010)
129. Wilkerson, J. L. et al. 2012 Intrathecal cannabilactone CB2R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain 153, 1091-1106. doi:10.1016/j.pain.2012.02.015)